Brought to you by 
Apoptogen, Exogen merge, form CNS drug co. Aegera
03 Nov 2020
Executive Summary
Private Canadian biotech start-ups Apoptogen and Exogen Neurosciences will merge to form a new company called Aegera Therapeutics Inc., which will develop therapeutics for cancer and neurodegenerative diseases such as Parkinson's and Alzheimer's.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Apoptogen, Exogen merge, form CNS drug co. Aegera
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice